Lilly Invests $6 Billion in Alabama Facility for Pharmaceutical Production
Eli Lilly and Company is set to invest over $6 billion in a new pharmaceutical manufacturing facility in Huntsville, Alabama. This investment marks a significant expansion of Lilly’s U.S. manufacturing capabilities and will create 3,450 jobs in the region.
Lilly’s Investment in Huntsville
Announced on December 9, 2025, the manufacturing site will focus on producing active pharmaceutical ingredients (APIs) for small molecule synthetic and peptide medicines. Notably, it will also manufacture orforglipron, Lilly’s first oral GLP-1 receptor agonist intended for obesity treatment.
Economic Impact
The construction of the facility is projected to generate 3,000 construction jobs, creating opportunities across various sectors. For every dollar invested by Lilly, the company anticipates an additional four dollars in local economic activity.
- Investment Amount: Over $6 billion
- Jobs Created: 3,450 total (450 permanent positions and 3,000 construction jobs)
- Facility Completion Date: Expected in 2032
Governor Kay Ivey expressed pride in the announcement, highlighting Alabama’s strong legacy in biosciences and innovation. Huntsville was selected for the new facility based on its skilled workforce and proximity to the HudsonAlpha Institute for Biotechnology, which supports vital workforce training and research.
Advanced Manufacturing Techniques
To enhance operations, Lilly will implement state-of-the-art technologies, including machine learning and digital automation. These advancements are aimed at streamlining processes and ensuring high-quality medicine production.
Executive Vice President Edgardo Hernandez emphasized Lilly’s commitment to sustainable manufacturing practices. The facility will focus on minimizing waste and achieving carbon neutrality, thereby reinforcing Lilly’s environmental stewardship.
Future Plans
This Alabama facility is part of Lilly’s broader strategy to bolster domestic production across various therapeutic areas. Along with the Huntsville site, Lilly has announced plans for manufacturing in Texas and Virginia and is expanding operations in Puerto Rico. Another U.S. location is expected to be unveiled soon.
Lilly’s investment in Huntsville is more than just a manufacturing initiative; it represents a significant effort to strengthen the pharmaceutical supply chain in the U.S. This project illustrates Lilly’s dedication to improving healthcare accessibility while fostering economic growth within the local community.
